NR1H4 and Hepatic fibrosis: Several in vivo studies using the steroid-based FXR agonist, obeticholic acid (OCA, aka 6-ethyl-CDCA or INT-747), have shown hepatoprotective effects in animal models of cholestasis and hepatic fibrosis.6